Fig. 4: Survival analysis by ctDNA burden and HRD-related mutations in prostate cancer. | British Journal of Cancer

Fig. 4: Survival analysis by ctDNA burden and HRD-related mutations in prostate cancer.

From: Functional footprints of homologous recombination deficiency in prostate cancer revealed by ctDNA fragmentation and transcription factor accessibility

Fig. 4

Overall survival (OS) of patients stratified by a tumour fraction (TF), b presence of TP53 or RB1 mutations, c presence of BRCA/PALB2 mutations, and d no pathogenic mutations detected, detected TP53/RB1 mutations, detected BRCA/PALB2 only, and detected TP53/RB1/BRCA/PALB2 mutations. Progression-free survival (PFS) of patients stratified by e tumour fraction (TF), f presence of TP53 or RB1 mutations, g presence of BRCA/PALB2 mutations, and h no pathogenic mutations detected, detected TP53/RB1 mutations, detected BRCA/PALB2 only, and detected TP53/RB1/BRCA/PALB2 mutations. Median survival times are indicated in the legend. Hazard ratios (HR), 95% confidence intervals (CI), and log-rank p-values were derived from Cox proportional hazards models and pairwise log-rank tests. Censoring is shown with vertical tick marks, and at-risk counts are displayed below each curve.

Back to article page